Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it plans to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD).
This decision follows an analysis of topline data from the Phase 2 RHO study which showed favourable safety, efficacy and biomarker results, confirming the therapeutic potential of efgartigimod.
With primary Sjogren's disease lacking FDA-approved treatments, efgartigimod offers promise as a potential alternative therapy for patients.
Sjogren's disease, characterised by immune-mediated destruction of exocrine glands, predominantly affects women. Common symptoms include dry eyes and mouth, fatigue, joint point and impaired cognitive function, and a substantial subset of patients suffer from extraglandular systemic disease.
Designed to target disease-causing immunoglobulin G antibodies, efgartigimod has demonstrated clinical efficacy across multiple endpoints.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment